{"id":70027,"date":"2026-07-15T12:40:36","date_gmt":"2026-07-15T04:40:36","guid":{"rendered":"https:\/\/flcube.com\/?p=70027"},"modified":"2026-07-15T12:40:37","modified_gmt":"2026-07-15T04:40:37","slug":"hansoh-pharmaceutical-secures-2-3b-il-23-deal-and-strategic-stake-in-avere-nextcure-merger","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70027","title":{"rendered":"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hansoh Pharmaceutical (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>)<\/strong> announced a <strong>dual strategic transaction<\/strong> involving its portfolio company <strong>Avere Therapeutics, Inc.<\/strong>, including an <strong>exclusive global license agreement<\/strong> for <strong>HS-20118 (AVR-001)<\/strong> and a <strong>significant equity stake<\/strong> in Avere&#8217;s <strong>all-stock merger with NextCure, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/NXTC:NASDAQ\">NASDAQ: NXTC<\/a>)<\/strong>. The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>License Agreement<\/strong><\/td><td>Exclusive global rights to HS-20118 excluding Greater China<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 120 million<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 2.18 billion (development and sales-related)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Mid-single to low-double-digit percentage on net sales<\/td><\/tr><tr><td><strong>Equity Stake<\/strong><\/td><td>30-40% of combined entity on fully diluted basis<\/td><\/tr><tr><td><strong>Territory Excluded<\/strong><\/td><td>Mainland China, Hong Kong, Macau, Taiwan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-amp-development-strategy\" class=\"wp-block-heading\">Asset Profile &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> HS-20118 (AVR-001) &#8211; cyclic peptide IL-23 receptor antagonist<\/li>\n\n\n\n<li><strong>Indication Focus:<\/strong> Oral therapies for IL-23-driven inflammatory diseases<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Preclinical\/early clinical (specific stage not disclosed)<\/li>\n\n\n\n<li><strong>Portfolio Company:<\/strong> Avere Therapeutics established as Hansoh Pharma spin-out focused on IL-23 pathway<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-merger-integration-public-market-acceleration\" class=\"wp-block-heading\">Merger Integration \u2013 Public Market Acceleration<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Entity<\/th><th>Contribution<\/th><th>Strategic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Avere Therapeutics<\/strong><\/td><td>Differentiated oral IL-23 program (HS-20118)<\/td><td>Novel mechanism addressing inflammatory disease market<\/td><\/tr><tr><td><strong>NextCure, Inc.<\/strong><\/td><td>Public listing structure (Nasdaq: NXTC)<\/td><td>Accelerated development timeline through public market access<\/td><\/tr><tr><td><strong>Combined Entity<\/strong><\/td><td>Avere Therapeutics, Inc. (ticker: AVRX)<\/td><td>Enhanced capital access and development resources<\/td><\/tr><tr><td><strong>Transaction Timeline<\/strong><\/td><td>Expected close in H2 2026<\/td><td>Rapid execution to capitalize on IL-23 market opportunity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The merger creates a publicly traded entity with a differentiated oral IL-23 antagonist positioned to compete in the $20B+ inflammatory disease market dominated by biologic therapies.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-positioning\" class=\"wp-block-heading\">Market Impact &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-23 Inhibitor Market:<\/strong> Oral IL-23 antagonists represent a significant advancement over injectable biologics, offering improved patient convenience and compliance<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Cyclic peptide approach may provide superior selectivity and safety profile compared to monoclonal antibody competitors<\/li>\n\n\n\n<li><strong>Strategic Value Creation:<\/strong> Hansoh retains Greater China rights while monetizing global potential through upfront payments, milestones, royalties, and equity appreciation<\/li>\n\n\n\n<li><strong>Financial Upside:<\/strong> Total potential deal value of $2.3B plus equity stake in publicly traded entity creates multiple value realization pathways<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the license agreement, merger transaction, and clinical development of HS-20118. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, merger completion, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[65,363,1182,4161,4160,4770],"class_list":["post-70027","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-nasdaq-nxtc","tag-nextcure","tag-travere-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere&#039;s all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70027\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere&#039;s all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70027\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T04:40:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T04:40:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70027#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70027\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger\",\"datePublished\":\"2026-07-15T04:40:36+00:00\",\"dateModified\":\"2026-07-15T04:40:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70027\"},\"wordCount\":390,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"NASDAQ: NXTC\",\"NextCure\",\"Travere Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70027#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70027\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70027\",\"name\":\"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-15T04:40:36+00:00\",\"dateModified\":\"2026-07-15T04:40:37+00:00\",\"description\":\"Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere's all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70027#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70027\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70027#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere's all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70027","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger","og_description":"Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere's all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.","og_url":"https:\/\/flcube.com\/?p=70027","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-15T04:40:36+00:00","article_modified_time":"2026-07-15T04:40:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70027#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70027"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger","datePublished":"2026-07-15T04:40:36+00:00","dateModified":"2026-07-15T04:40:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70027"},"wordCount":390,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Hansoh Pharmaceutical","HKG: 3692","NASDAQ: NXTC","NextCure","Travere Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70027#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70027","url":"https:\/\/flcube.com\/?p=70027","name":"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-15T04:40:36+00:00","dateModified":"2026-07-15T04:40:37+00:00","description":"Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere's all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70027#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70027"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70027#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70027"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70027\/revisions"}],"predecessor-version":[{"id":70030,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70027\/revisions\/70030"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}